APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Vector Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Recombinant Vector Vaccines Market Outlook and Growth Opportunities 2026

Report ID 174031910422 December 2025192 pages

Choose your research edition.

Industry ResearchRecombinant Vector Vaccines Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Vector Vaccines Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Recombinant Vector Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Vector Vaccines Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Vector Vaccines Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Recombinant Vector Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Recombinant Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Recombinant Vector Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Recombinant Vector Vaccines market include SANOFI PASTEUR S.A., CNBG, SINOVAC BIOTECH, Zhifei, GSK, Hualan Bio, ChengDa Bio, NuoCheng Bio and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Vector Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Vector Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Vector Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Vector Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Vector Vaccines Segment by Company

SANOFI PASTEUR S.A.

CNBG

SINOVAC BIOTECH

Zhifei

GSK

Hualan Bio

ChengDa Bio

NuoCheng Bio

Novartis

Kangtai

Changsheng Life

Recombinant Vector Vaccines Segment by Type

Varicella

Influenza

Hepatitis

Pneumococcal

Pertussis, Diphtheria, tetanus

Others

Recombinant Vector Vaccines Segment by Application

For Adult

For Child

Recombinant Vector Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Recombinant Vector Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Recombinant Vector Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Recombinant Vector Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Recombinant Vector Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Vector Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Vector Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Vector Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Vector Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant Vector Vaccines industry.

Chapter 3: Detailed analysis of Recombinant Vector Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Recombinant Vector Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Recombinant Vector Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Recombinant Vector Vaccines Industry Trends Table 2. Recombinant Vector Vaccines Industry Drivers Table 3. Recombinant Vector Vaccines Industry Opportunities and Challenges Table 4. Recombinant Vector Vaccines Industry Restraints Table 5. Global Recombinant Vector Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Recombinant Vector Vaccines Revenue Share by Company (2021-2026) Table 7. Global Recombinant Vector Vaccines Sales Volume by Company (k units) & (2021-2026) Table 8. Global Recombinant Vector Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Recombinant Vector Vaccines Average Price (US$/unit) of Company (2021-2026) Table 10. Global Recombinant Vector Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Recombinant Vector Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Recombinant Vector Vaccines Company, Product Type & Application Table 13. Global Recombinant Vector Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Vector Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Varicella Table 18. Significant Companies of Influenza Table 19. Significant Companies of Hepatitis Table 20. Significant Companies of Pneumococcal Table 21. Significant Companies of Pertussis, Diphtheria, tetanus Table 22. Significant Companies of Others Table 23. Global Recombinant Vector Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Recombinant Vector Vaccines Sales Volume by Type (2021-2026) & (k units) Table 25. Global Recombinant Vector Vaccines Sales Volume by Type (2027-2032) & (k units) Table 26. Global Recombinant Vector Vaccines Sales Volume Share by Type (2021-2026) Table 27. Global Recombinant Vector Vaccines Sales Volume Share by Type (2027-2032) Table 28. Global Recombinant Vector Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Recombinant Vector Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Recombinant Vector Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Recombinant Vector Vaccines Sales Value Share by Type (2021-2026) Table 32. Global Recombinant Vector Vaccines Sales Value Share by Type (2027-2032) Table 33. Significant Companies of For Adult Table 34. Significant Companies of For Child Table 35. Global Recombinant Vector Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Recombinant Vector Vaccines Sales Volume by Application (2021-2026) & (k units) Table 37. Global Recombinant Vector Vaccines Sales Volume by Application (2027-2032) & (k units) Table 38. Global Recombinant Vector Vaccines Sales Volume Share by Application (2021-2026) Table 39. Global Recombinant Vector Vaccines Sales Volume Share by Application (2027-2032) Table 40. Global Recombinant Vector Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Recombinant Vector Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Recombinant Vector Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Recombinant Vector Vaccines Sales Value Share by Application (2021-2026) Table 44. Global Recombinant Vector Vaccines Sales Value Share by Application (2027-2032) Table 45. Global Recombinant Vector Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Recombinant Vector Vaccines Sales by Region (2021-2026) & (k units) Table 47. Global Recombinant Vector Vaccines Sales Market Share by Region (2021-2026) Table 48. Global Recombinant Vector Vaccines Sales by Region (2027-2032) & (k units) Table 49. Global Recombinant Vector Vaccines Sales Market Share by Region (2027-2032) Table 50. Global Recombinant Vector Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Recombinant Vector Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Recombinant Vector Vaccines Sales Value Share by Region (2021-2026) Table 53. Global Recombinant Vector Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Recombinant Vector Vaccines Sales Value Share by Region (2027-2032) Table 55. Global Recombinant Vector Vaccines Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global Recombinant Vector Vaccines Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global Recombinant Vector Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global Recombinant Vector Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Recombinant Vector Vaccines Sales by Country (2021-2026) & (k units) Table 60. Global Recombinant Vector Vaccines Sales Market Share by Country (2021-2026) Table 61. Global Recombinant Vector Vaccines Sales by Country (2027-2032) & (k units) Table 62. Global Recombinant Vector Vaccines Sales Market Share by Country (2027-2032) Table 63. Global Recombinant Vector Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Recombinant Vector Vaccines Sales Value Market Share by Country (2021-2026) Table 65. Global Recombinant Vector Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Recombinant Vector Vaccines Sales Value Market Share by Country (2027-2032) Table 67. SANOFI PASTEUR S.A. Company Information Table 68. SANOFI PASTEUR S.A. Business Overview Table 69. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolio Table 71. SANOFI PASTEUR S.A. Recent Development Table 72. CNBG Company Information Table 73. CNBG Business Overview Table 74. CNBG Recombinant Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. CNBG Recombinant Vector Vaccines Product Portfolio Table 76. CNBG Recent Development Table 77. SINOVAC BIOTECH Company Information Table 78. SINOVAC BIOTECH Business Overview Table 79. SINOVAC BIOTECH Recombinant Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolio Table 81. SINOVAC BIOTECH Recent Development Table 82. Zhifei Company Information Table 83. Zhifei Business Overview Table 84. Zhifei Recombinant Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Zhifei Recombinant Vector Vaccines Product Portfolio Table 86. Zhifei Recent Development Table 87. GSK Company Information Table 88. GSK Business Overview Table 89. GSK Recombinant Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. GSK Recombinant Vector Vaccines Product Portfolio Table 91. GSK Recent Development Table 92. Hualan Bio Company Information Table 93. Hualan Bio Business Overview Table 94. Hualan Bio Recombinant Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Hualan Bio Recombinant Vector Vaccines Product Portfolio Table 96. Hualan Bio Recent Development Table 97. ChengDa Bio Company Information Table 98. ChengDa Bio Business Overview Table 99. ChengDa Bio Recombinant Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. ChengDa Bio Recombinant Vector Vaccines Product Portfolio Table 101. ChengDa Bio Recent Development Table 102. NuoCheng Bio Company Information Table 103. NuoCheng Bio Business Overview Table 104. NuoCheng Bio Recombinant Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. NuoCheng Bio Recombinant Vector Vaccines Product Portfolio Table 106. NuoCheng Bio Recent Development Table 107. Novartis Company Information Table 108. Novartis Business Overview Table 109. Novartis Recombinant Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Novartis Recombinant Vector Vaccines Product Portfolio Table 111. Novartis Recent Development Table 112. Kangtai Company Information Table 113. Kangtai Business Overview Table 114. Kangtai Recombinant Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Kangtai Recombinant Vector Vaccines Product Portfolio Table 116. Kangtai Recent Development Table 117. Changsheng Life Company Information Table 118. Changsheng Life Business Overview Table 119. Changsheng Life Recombinant Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Changsheng Life Recombinant Vector Vaccines Product Portfolio Table 121. Changsheng Life Recent Development Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Recombinant Vector Vaccines Distributors List Table 125. Recombinant Vector Vaccines Customers List Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Recombinant Vector Vaccines Product Image Figure 2. Global Recombinant Vector Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Vector Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Recombinant Vector Vaccines Sales (2021-2032) & (k units) Figure 5. Global Recombinant Vector Vaccines Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Recombinant Vector Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Varicella Image Figure 10. Influenza Image Figure 11. Hepatitis Image Figure 12. Pneumococcal Image Figure 13. Pertussis, Diphtheria, tetanus Image Figure 14. Others Image Figure 15. Global Recombinant Vector Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Recombinant Vector Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Recombinant Vector Vaccines Sales Volume Share by Type (2021-2032) Figure 18. Global Recombinant Vector Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Recombinant Vector Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Recombinant Vector Vaccines Sales Value Share by Type (2021-2032) Figure 21. For Adult Image Figure 22. For Child Image Figure 23. Global Recombinant Vector Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Recombinant Vector Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Recombinant Vector Vaccines Sales Volume Share by Application (2021-2032) Figure 26. Global Recombinant Vector Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Recombinant Vector Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Recombinant Vector Vaccines Sales Value Share by Application (2021-2032) Figure 29. Global Recombinant Vector Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Recombinant Vector Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Recombinant Vector Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Recombinant Vector Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Recombinant Vector Vaccines Sales Value (2021-2032) & (US$ Million) Figure 34. North America Recombinant Vector Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Recombinant Vector Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Recombinant Vector Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Recombinant Vector Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Recombinant Vector Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Recombinant Vector Vaccines Sales Value (2021-2032) & (US$ Million) Figure 40. South America Recombinant Vector Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Recombinant Vector Vaccines Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Recombinant Vector Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Recombinant Vector Vaccines Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Recombinant Vector Vaccines Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Varicella
  • Influenza
  • Hepatitis
  • Pneumococcal
  • Pertussis, Diphtheria, tetanus
  • Others
Applications
  • For Adult
  • For Child
Companies covered
  • SANOFI PASTEUR S.A.
  • CNBG
  • SINOVAC BIOTECH
  • Zhifei
  • GSK
  • Hualan Bio
  • ChengDa Bio
  • NuoCheng Bio
  • Novartis
  • Kangtai
  • Changsheng Life

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Recombinant Vector Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Recombinant Vector Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Recombinant Vector Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Recombinant Vector Vaccines Market Dynamics
  1. 2.1 Recombinant Vector Vaccines Industry Trends
  2. 2.2 Recombinant Vector Vaccines Industry Drivers
  3. 2.3 Recombinant Vector Vaccines Industry Opportunities and Challenges
  4. 2.4 Recombinant Vector Vaccines Industry Restraints
3 Recombinant Vector Vaccines Market by Company
  1. 3.1 Global Recombinant Vector Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Recombinant Vector Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Recombinant Vector Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Recombinant Vector Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Recombinant Vector Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Recombinant Vector Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Recombinant Vector Vaccines Company Product Type and Application
  8. 3.8 Global Recombinant Vector Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Recombinant Vector Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Recombinant Vector Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Recombinant Vector Vaccines Market by Type
  1. 4.1 Recombinant Vector Vaccines Type Introduction
  2. 4.1.1 Varicella
  3. 4.1.2 Influenza
  4. 4.1.3 Hepatitis
  5. 4.1.4 Pneumococcal
  6. 4.1.5 Pertussis, Diphtheria, tetanus
  7. 4.1.6 Others
  8. 4.2 Global Recombinant Vector Vaccines Sales Volume by Type
  9. 4.2.1 Global Recombinant Vector Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Recombinant Vector Vaccines Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Recombinant Vector Vaccines Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Recombinant Vector Vaccines Sales Value by Type
  13. 4.3.1 Global Recombinant Vector Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Recombinant Vector Vaccines Sales Value by Type (2021-2032)
  15. 4.3.3 Global Recombinant Vector Vaccines Sales Value Share by Type (2021-2032)
5 Recombinant Vector Vaccines Market by Application
  1. 5.1 Recombinant Vector Vaccines Application Introduction
  2. 5.1.1 For Adult
  3. 5.1.2 For Child
  4. 5.2 Global Recombinant Vector Vaccines Sales Volume by Application
  5. 5.2.1 Global Recombinant Vector Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Recombinant Vector Vaccines Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Recombinant Vector Vaccines Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Recombinant Vector Vaccines Sales Value by Application
  9. 5.3.1 Global Recombinant Vector Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Recombinant Vector Vaccines Sales Value by Application (2021-2032)
  11. 5.3.3 Global Recombinant Vector Vaccines Sales Value Share by Application (2021-2032)
6 Recombinant Vector Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Recombinant Vector Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Vector Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Vector Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Recombinant Vector Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Recombinant Vector Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Recombinant Vector Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Recombinant Vector Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Recombinant Vector Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Recombinant Vector Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Recombinant Vector Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Recombinant Vector Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Recombinant Vector Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Recombinant Vector Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Recombinant Vector Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Recombinant Vector Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Recombinant Vector Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Recombinant Vector Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Recombinant Vector Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Recombinant Vector Vaccines Sales Value Share by Country, 2025 VS 2032
7 Recombinant Vector Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Recombinant Vector Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Recombinant Vector Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Recombinant Vector Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Recombinant Vector Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Recombinant Vector Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Recombinant Vector Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Recombinant Vector Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Recombinant Vector Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Recombinant Vector Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Recombinant Vector Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Recombinant Vector Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 SANOFI PASTEUR S.A.
  2. 8.1.1 SANOFI PASTEUR S.A. Company Information
  3. 8.1.2 SANOFI PASTEUR S.A. Business Overview
  4. 8.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolio
  6. 8.1.5 SANOFI PASTEUR S.A. Recent Developments
  7. 8.2 CNBG
  8. 8.2.1 CNBG Company Information
  9. 8.2.2 CNBG Business Overview
  10. 8.2.3 CNBG Recombinant Vector Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CNBG Recombinant Vector Vaccines Product Portfolio
  12. 8.2.5 CNBG Recent Developments
  13. 8.3 SINOVAC BIOTECH
  14. 8.3.1 SINOVAC BIOTECH Company Information
  15. 8.3.2 SINOVAC BIOTECH Business Overview
  16. 8.3.3 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolio
  18. 8.3.5 SINOVAC BIOTECH Recent Developments
  19. 8.4 Zhifei
  20. 8.4.1 Zhifei Company Information
  21. 8.4.2 Zhifei Business Overview
  22. 8.4.3 Zhifei Recombinant Vector Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Zhifei Recombinant Vector Vaccines Product Portfolio
  24. 8.4.5 Zhifei Recent Developments
  25. 8.5 GSK
  26. 8.5.1 GSK Company Information
  27. 8.5.2 GSK Business Overview
  28. 8.5.3 GSK Recombinant Vector Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GSK Recombinant Vector Vaccines Product Portfolio
  30. 8.5.5 GSK Recent Developments
  31. 8.6 Hualan Bio
  32. 8.6.1 Hualan Bio Company Information
  33. 8.6.2 Hualan Bio Business Overview
  34. 8.6.3 Hualan Bio Recombinant Vector Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hualan Bio Recombinant Vector Vaccines Product Portfolio
  36. 8.6.5 Hualan Bio Recent Developments
  37. 8.7 ChengDa Bio
  38. 8.7.1 ChengDa Bio Company Information
  39. 8.7.2 ChengDa Bio Business Overview
  40. 8.7.3 ChengDa Bio Recombinant Vector Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 ChengDa Bio Recombinant Vector Vaccines Product Portfolio
  42. 8.7.5 ChengDa Bio Recent Developments
  43. 8.8 NuoCheng Bio
  44. 8.8.1 NuoCheng Bio Company Information
  45. 8.8.2 NuoCheng Bio Business Overview
  46. 8.8.3 NuoCheng Bio Recombinant Vector Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 NuoCheng Bio Recombinant Vector Vaccines Product Portfolio
  48. 8.8.5 NuoCheng Bio Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Recombinant Vector Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Recombinant Vector Vaccines Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 Kangtai
  56. 8.10.1 Kangtai Company Information
  57. 8.10.2 Kangtai Business Overview
  58. 8.10.3 Kangtai Recombinant Vector Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Kangtai Recombinant Vector Vaccines Product Portfolio
  60. 8.10.5 Kangtai Recent Developments
  61. 8.11 Changsheng Life
  62. 8.11.1 Changsheng Life Company Information
  63. 8.11.2 Changsheng Life Business Overview
  64. 8.11.3 Changsheng Life Recombinant Vector Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Changsheng Life Recombinant Vector Vaccines Product Portfolio
  66. 8.11.5 Changsheng Life Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Vector Vaccines Value Chain Analysis
  2. 9.1.1 Recombinant Vector Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Vector Vaccines Sales Mode & Process
  6. 9.2 Recombinant Vector Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Vector Vaccines Distributors
  9. 9.2.3 Recombinant Vector Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst